Showing results (1-10 of 104) with videos related to
Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2020
Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the IssueZofia Piotrowska, Aaron N HataPharmacology & Therapeutics|September 17, 2004
Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulationAaron N Hata, Richard M BreyerCancer Discovery|January 11, 2020
Can the Help Match the Hype? KRASG12C-Specific Inhibitors and BeyondSamuel J Klempner, Aaron N HataCancers|June 2, 2021
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in CancerHeidie Frisco Cabanos, Aaron N HataPharmacology & Therapeutics|March 11, 2020
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insightsCatherine B Meador, Aaron N HataPharmacology & Therapeutics|August 20, 2018
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunitiesSatoshi Yoda, Ibiayi Dagogo-Jack, Aaron N HataThe Journal of Biological Chemistry|July 21, 2005
Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2Aaron N Hata, Terry P Lybrand, Richard M BreyerThe Oncologist|August 4, 2021
MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 SkippingJonathan M Tsai, Aaron N Hata, Jochen K LennerzCancer Discovery|April 22, 2015
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsAaron N Hata, Jeffrey A Engelman, Anthony C FaberPageof 11